Adverum Biotechnologies Inc - Company Profile
Powered by 
All the data and insights you need on Adverum Biotechnologies Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Adverum Biotechnologies Inc Strategy Report
- Understand Adverum Biotechnologies Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Adverum Biotechnologies Inc (Adverum), formerly Avalanche Biotechnologies Inc, is a clinical-stage gene therapy company. The company focuses on developing therapies to treat ocular diseases. Its product pipeline includes Ixo-vec drug candidate to treat wet age-related macular degeneration (AMD); ADVM for treatment of blue cone monochromacy (BCM); and LX2006 GTx to treat friedreich’s ataxia. Adverum also develops other drug programs for retinitis pigmentosa, and geographic atrophy. The company develops drugs in collaboration with Gensight Biologics, Lexeo Therapeutics, and Ray Therapeutics. Adverum is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
100 Cardinal Way, Redwood City, California, 94063
Website
adverum.com
Telephone
1 650 6569323
No of Employees
121
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADVM (NASD)
Revenue (2022)
$3.6M
EPS
XYZ
Net Income (2022)
XYZ
24.2%
(2022 vs 2021)
Market Cap*
$231.4M
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Adverum Biotechnologies Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Ixo-vec: Wet Age-Related Macular Degeneration |
| Geographic Atrophy: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In April, the company announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency granted Ixo-vec , an investigational gene therapy for the treatment of wet AMD. |
| 2022 | Regulatory Approval | In June, the company announced that the European Medicines Agency (EMA) granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (wet AMD). |
| 2017 | Acquisitions/Mergers/Takeovers | In August,Adverum Biotechnologies acquired Annapurna Therapeutics SAS. |
Competitor Comparison
| Key Parameters | Adverum Biotechnologies Inc | Voyager Therapeutics Inc | Ocuphire Pharma Inc | TRACON Pharmaceuticals Inc | Axim Biotechnologies Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Redwood City | Lexington | Farmington Hills | San Diego | San Diego |
| State/Province | California | Massachusetts | Michigan | California | California |
| No. of Employees | 121 | 162 | 14 | 17 | 6 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick Machado | Chairman | Executive Board | 2019 | 59 |
| Laurent Fischer | Chief Executive Officer; President; Director | Executive Board | 2020 | 59 |
| Linda Rubinstein | Chief Financial Officer | Senior Management | 2021 | 56 |
| Kishor Peter Soparkar | Chief Operating Officer | Senior Management | 2021 | 52 |
| Andrew Ramelmeier | Chief Technology Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward